Phenoconversion and therapeutic drug monitoring

Phenoconversion and Therapeutic Drug Monitoring

Disclosures of Competing Interests: This letter to the editor was completed without any external funding. 18 No commercial organizations had any role in the writing of this paper for publication. 20 request from the corresponding author) and declares: no financial relationships with any organizations that 21 might have an interest in the submitted work in the previous 3 years.

Phenoconversion and therapeutic drug monitoring.

therapeutic drug monitoring

0

A Review on Therapeutic Drug Monitoring of Immunosuppressant Drugs

Immunosuppressants require therapeutic drug monitoring because of their narrow therapeutic index and significant inter-individual variability in blood concentrations. This variability can be because of factors like drug-nutrient interactions, drug-disease interactions, renal-insufficiency, inflammation and infection, gender, age, polymorphism and liver mass. Drug monitoring is widely practiced ...

Therapeutic drug monitoring

(Suggestions are based on Level III and IV evidence) • In both adults and children, C2 monitoring of CSA is superior to C0 as a predictor of AUC 0–4 and AUC 0–12. The C3 level is marginally superior to C2 for AUC 0–12. • Targeting AUC 0–4 levels for CSA of greater than 4400 ng/mL or C2 levels of greater than 1.5 by the end of the first week post transplant is associated with less acute rejectio...